#glp1ra — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #glp1ra, aggregated by home.social.
-
DATE: August 22, 2026 at 08:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Weight-loss drugs linked to rare eye condition in massive data review
URL: https://www.psypost.org/weight-loss-drugs-linked-to-rare-eye-condition-in-massive-data-review/
A massive new review of medical data indicates that patients taking popular weight-loss and diabetes medications may face a higher risk of developing a rare but serious eye condition. The research, published in Neurology, found that people using semaglutide experience sudden vision loss at a higher rate than those using other treatments. The results offer a detailed look at the potential side effects associated with this rapidly growing class of drugs.
Nonarteritic anterior ischemic optic neuropathy is a condition in which blood flow to the optic nerve is restricted. This vital nerve connects the eye to the brain, and a lack of blood flow causes the tissue to swell. The swelling results in sudden, painless vision loss, typically in just one eye. The condition frequently leads to permanent visual damage, making it the leading cause of acute optic nerve injury in older adults.
Risk factors for this type of nerve damage include high blood pressure, type 2 diabetes, and sleep apnea. Certain anatomical features, such as having a crowded optic nerve head in the back of the eye, can also increase a person’s vulnerability. Because these risk factors overlap heavily with metabolic diseases, isolating the true cause of the neuropathy in patients is often difficult.
Medications like semaglutide belong to a class of drugs known as glucagon-like peptide-1 receptor agonists. These drugs mimic a naturally occurring hormone in the body to delay stomach emptying and reduce a person’s appetite. They also help the pancreas release insulin in response to meals, which controls blood sugar levels. Doctors prescribe them widely to treat type 2 diabetes and clinical obesity.
Millions of patients now take these medications globally, making the identification of rare side effects a public health priority. Recent observational studies looking at these medications and eye health have produced conflicting results. Some individual studies suggested the drugs increased the risk of optic neuropathy. Other analyses found no association or even hinted at a protective effect against vision loss.
To synthesize the available data and resolve these contradictions, a team of researchers conducted a comprehensive meta-analysis. Thanansayan Dhivagaran, Fahad Butt, and Luckshann Arunasalam of the University of Western Ontario led the study. They collaborated with Edward Margolin and other colleagues from the University of Toronto.
The researchers systematically searched medical databases for observational studies published up to April 2025. They specifically looked for studies comparing the risk of optic neuropathy between patients using the medications and those using alternative treatments. The team established strict criteria to avoid counting the same patients multiple times across overlapping data registries.
They pooled data from five main studies to form a massive sample of 1,593,554 patients. This group included 682,456 patients using semaglutide and 911,098 using other drugs. The team used specialized Bayesian statistical models to calculate the relative risk and the overall incidence of the eye condition. These models are particularly useful for analyzing extremely rare medical events.
The primary analysis revealed that semaglutide use was associated with a 152 percent higher risk of developing the optic neuropathy compared to the use of alternative medications. The statistical models showed a 99.9 percent probability that the true relative risk was greater than one. Despite this relative increase, the absolute number of cases remained very low in the population.
The researchers calculated an overall incidence of 118 cases per 100,000 semaglutide users. Across all medications in this class, including dulaglutide and exenatide, the incidence was 85 cases per 100,000 users. These numbers translate to less than a fraction of a percent of all patients taking the drugs.
The team then looked specifically at patients with diabetes to see if the underlying condition influenced the risk. They analyzed data from five studies covering roughly 1.59 million individuals. This massive subset was split between semaglutide users and those managing their diabetes with other treatments.
Among patients with diabetes, semaglutide users had a 141 percent higher risk of developing the eye condition compared to non-users. The absolute risk in this specific group was estimated at 125 cases per 100,000 semaglutide users. The statistical evidence supporting this association remained extremely strong across multiple sensitivity analyses.
Next, the researchers examined the risk among patients prescribed semaglutide specifically for obesity. They pooled data from two studies that included a large sample of 116,613 patients. This group consisted of 58,254 semaglutide users and 58,359 individuals taking alternative weight-loss medications.
In the obesity subgroup, semaglutide was associated with a 77 percent higher risk of the optic neuropathy compared to the alternative treatments. The incidence rate in this group was notably higher at 712 cases per 100,000 semaglutide users. The researchers noted that the statistical certainty for this specific subgroup was moderate rather than strong.
To provide more context, the researchers evaluated how semaglutide compared directly to other specific classes of drugs. They analyzed data comparing semaglutide to SGLT2 inhibitors, which are another common type of diabetes medication. This comparison involved a massive sample of nearly 948,000 patients.
Patients taking semaglutide had roughly twice the risk of developing the vision condition compared to those taking SGLT2 inhibitors. The team also compared semaglutide to other drugs within the same class in a sample of about 865,000 patients. When compared to users of other similar medications, semaglutide users faced a 61 percent higher risk.
The exact biological reason for this association remains unknown. One hypothesis suggests that the blood pressure-lowering effects of the medications might reduce blood flow to the optic nerve head. Animal and human studies show that these drugs interact with bodily systems regulating sodium absorption and blood pressure. In susceptible individuals, this chronic reduction in local blood pressure could trigger the neuropathy.
Weight loss itself might also indirectly lead to lower blood pressure, compounding the effect. Patients experiencing rapid weight loss may require adjustments to their existing blood pressure medications to prevent sudden drops. If these adjustments are not made, the resulting low blood pressure might leave the optic nerve vulnerable to injury.
Because this meta-analysis relied exclusively on observational data, the results cannot prove that semaglutide directly causes the eye condition. Patients prescribed these newer medications often have more severe or poorly controlled metabolic diseases. Advanced diabetes and obesity are themselves major drivers of vascular damage and nerve problems. This underlying disease severity could be contributing to the higher rates of vision loss in the treatment groups.
The researchers also noted that it takes time for the medications to reach their maximum effect in the body. Cases of vision loss that occur shortly after a patient starts the drug might reflect preexisting vascular risks rather than a side effect of the treatment. Additionally, the studies included in the review mostly featured White populations from the United States, Denmark, and Norway. This demographic limitation restricts how broadly the findings can be applied to other groups.
Health care providers must weigh this rare risk against the well-documented systemic benefits of the medications. Large clinical trials have shown that these drugs reduce the incidence of cardiovascular death, nonfatal heart attacks, and strokes. The medications may even protect against other prevalent eye diseases like diabetic retinopathy and glaucoma. For the vast majority of patients, the broad improvements in metabolic health likely outweigh the low absolute risk of this specific neuropathy.
Future research will need to track visual outcomes in patients over longer periods while strictly controlling for existing vascular risk factors. Prospective trials could help clarify the exact biological mechanisms linking the medications to blood flow changes in the eye. Until more data is available, the authors suggest that doctors discuss potential visual risks when prescribing these medications. Patients initiating therapy should seek prompt ophthalmic evaluation if they experience sudden visual changes.
The study, “Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Systematic Review and Meta-Analysis,” was authored by Thanansayan Dhivagaran, Fahad Butt, Luckshann Arunasalam, Isabel Bae, David Mikhail, Brendan K. Tao, Jim Shenchu Xie, Michael Balas, Marko Popovic, and Edward Margolin.
URL: https://www.psypost.org/weight-loss-drugs-linked-to-rare-eye-condition-in-massive-data-review/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #SemaglutideEyeRisk #OpticNeuropathy #GLP1RA #WeightLossMedication #DiabetesTreatment #EyeHealthUpdate #VisionLossAwareness #SGLT2vsGLP1 #MetabolicHealth #NeurologyResearch
-
Comprehensive update on diabetic kidney disease, cardiokidney metabolic syndrome, screening, diagnosis, and modern pharmacological treatments including SGLT2 inhibitors and MRAs for improved cardiorenal outcomes. #dkd #CKD #SGLT2i #GLP1RA www.slideshare.net/slideshow/ma...
Managing Diabetic Kidney Disea... -
I expect the #glp1ra online and in-real-life shaming and bullying to get worse after the publication of #SURPASS-CVOT #tirzepatide #dulaglutide.
I think my #gigablock game will surpass (pun intended) my peak of the early pandemic era esp after I have gone through the egfr data. -
I expect the #glp1ra online and in-real-life shaming and bullying to get worse after the publication of #SURPASS-CVOT #tirzepatide #dulaglutide. I think my #gigablock game will surpass (pun intended) my peak of the early pandemic era esp after I have gone through the egfr data.
-
@AusSMC
Yes! And (clear fluids excepted) consider a 24h fast before general anaesthesia. Nobody likes aspiration pneumonia. -
1000% this .... the need for personalization of #glp1ra dose has been rather obvious (and, in fact, was the part of the rationale) behind AWARD-11
-
1000% this .... the need for personalization of #glp1ra dose has been rather obvious (and, in fact, was the part of the rationale) behind AWARD-11
-
The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks
A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...
-
HR = exp(-0.38-0.19) ~ 0.57 (43% reduction in bad kidney juju) which is very close to the estimate of 0.54 given by @brendonneuen.bsky.social by extrapolating the effect sizes of the trials available at that time. Conclusions: 1. #rstats can answer clinical questions 2. Use #GLP1RA + #flozin /
-
The nice thing about knowing #rstats, is that one can often answer some clinical questions using public data. E.g. do I expect a benefit when combining #flozin and #Glp1RA in patients living with diabetes and kidney disease? Let's use 👇from www.sciencedirect.com/science/arti... to answer the Q 1/
-
Sorry, #dulaglutide med #trulicity; the more general description of these drugs is #glp1 receptor agonists.
Apparently various professional orgs have been kinda all over the map on whether or not to hold such meds pre-op, but now they are coalescing -- still without formal evidence-based guidance, mind you -- around 24-hour liquid diet in preoperative phase, especially for higher doses of the meds for patients on weekly regimens.
-
Nephrologis' take on the effect and impact of SGLT-2 inhibitors and GLP-1RA #diabetes https://www.slideshare.net/slideshow/nephrologist-s-take-on-the-effect-and-impact-of-sglt-2-inhibitors-and-glp-1-ras-on-kidney-disease-in-people-with-diabetes/271231000 via @SlideShare #DiabetesCare #CKD #flozins #GLP1RA
-
I really wish content creators, especially large ones, that do news and news commentary, would stop referring to GLP-1 drugs as weight loss drugs. This erases the problem that diabetics face with access to this drug through these major shortages.
This has been a diabetes drug for far longer than it was available for weight loss. And it’s only a second gen weight loss version of it that got popular.
-
So far, I'm having no negative side effects from restarting Mounjaro.
I'm also not experiencing the appetite suppression.
However, it seems my dawn/fotf is recovering on its own this morning without using insulin. So might be getting the benefits already.
Will have to monitor.
-
I was in a hurry to pick up my prescriptions. Tomorrow I will be going back to ask for an explanation how this is a 90 day supply of insulin.
On the bright side, I did also get Mounjaro 5mg. So there’s that. I think I’m going to wait on restarting it so I can build up some buffer supply.
-
Last night, while relaxing for the evening before bed, I was coasting around 110mg/dL BG. Which is super good for a diabetic. I went to bed. Benson woke me up because he needed to go potty and other attention (super rare for him to wake me up). I look at my watch and my CGM is reporting 180mg/dL. I pull up my app and it had spiked.
I’m supposed to still have a semi-functional pancreas as a far progressed T2D. So I decided not to correct it.
I floated around 170mg/dL all night and woke up to 190mg/dL and climbing.
My next doctor’s visit is in July, where I will request a c-peptide test to see what the effect on endogenous insulin has been while losing access to Mounjaro. I don’t think my diagnosis should change from T2D, but as time goes on I suspect my c-peptide result might look like an early T1D diagnosis, which is a potential progression of T2D.
Finally took that correction this morning.
Fun times with diabetes.
#Diabetes #T2D #BloodGlucose #Insulin #Mounjaro #GLP1RA #Frustration
-
With my GLP-1 drugs basically completely out of my system, my insulin sensitivity is a bit shot. My insulin use has gone up a little bit due to my ratios changing. But with my low carb diet with intermittent fasting, it didn’t go up a lot.
Need to update the doc with this info.
Still no signs of when the Mounjaro shortage will let up.